If the KI is defined by the free energy of binding to pglycoprotein, which kinetic parameters define the IC50 for the madin-darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?

Drug Metabolism and Disposition

Volumn 38, Issue 2, 2010, Pages 260-269

  Lumen, Annie Albin ^a,b   Acharya, Poulomi ^a,b,d   Polli, Joseph W ^b   Ayrton, Andrew ^c   Ellens, Harma ^b   Bentz, Joe ^a  

^a DREXEL UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DIGOXIN; ELACRIDAR; GLYCOPROTEIN P; LOPERAMIDE; QUINIDINE; VERAPAMIL; ABCB1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG PENETRATION; ENERGY; ENVIRONMENT; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KINETICS; MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN BINDING; ANIMAL; BIOLOGICAL MODEL; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; COMPUTER SIMULATION; DOG; DRUG EFFECT; DRUG INTERACTION; GENE; GENETICS; HUMAN; KIDNEY; METABOLISM; PHARMACOKINETICS; THERMODYNAMICS; TRANSPORT AT THE CELLULAR LEVEL;

POLLACHIUS POLLACHIUS;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; COMPUTER SIMULATION; DIGOXIN; DOGS; DRUG INTERACTIONS; GENES, MDR; HUMANS; KIDNEY; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACOKINETICS; PROTEIN BINDING; QUINIDINE; THERMODYNAMICS;

EID: 76149115533     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029843     Document Type: Article

References (39)

1. Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, and Bentz J (2008) Kinetic identification of membrane transporters that assist P-gp mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab Dispos 36:452-460.
2. Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H, and Bentz J (2006) P-gp expressed in a confluent monolayer of MDCKII-hMDR1 cells has more than one efflux pathway with cooperative binding sites. Biochemisty 45:15505-15519.
3. Balimane PV, Marino A, and Chong S (2008) P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate? AAPS J 10:577-586.
4. Bartholomé K, Rius M, Letschert K, Keller D, Timmer J, and Keppler D (2007) Data-based mathematical modeling of vectorial transport across double-transfected polarized cells. Drug Metab Dispos 35:1476-1481.
5. m. Pharm Res 22:1667-1677.
6. Borst P, Zelcer N, van de Wetering K, and Poolman B (2006) On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett 580:1085-1093.
7. Chang JH and Benet LZ (2005) Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol Pharm 2:428-434.
8. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, Glaeser H, Kim RB, Wood AJ, and Wilkinson GR (2006) Differential in vivo sensitivity to inhibition of Pglycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther 317:1012-1018.
10. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, and Warhurst G (2005) Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci 26:386-393.
11. Endres CJ, Hsiao P, Chung FS, and Unadkat JD (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517.
12. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P (2000) Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83:366-374.
13. Gao J, Murase O, Schowen RL, Aubé J, and Borchardt RT (2001) A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 18:171-176.
14. Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi- Szabó K, and Krajcsi P (2008) Utilization of membrane vesicles to study drug-ABC transporter interactions. Expert Opin Drug Metab Toxicol 4:721-732.
15. Hah JS, Ryu JW, Lee W, Kim BS, Lachaal M, Spangler RA, and Jung CY (2002) Transient changes in four GLUT4 compartments in rat adipocytes during the transition, insulinstimulated to basal: implications for the GLUT4 trafficking pathway. Biochemistry 41:14364-14371.
16. Ho NFH, Raub TJ, Burton PS, Bausuhn CL, Adson A, Audus KL, and Borchardt R (2000). Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers, in Transport Processes in Pharmaceutical Systems (Amidon GL and Lee V) pp. 219-316, Marcel Dekker, New York.
17. Kalvass JC and Pollack GM (2007) Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24:265-276.
18. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, and Hall MD (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86:368-377.
19. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, and Muszkat M (2008) Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology 109:1092-1099.
20. Lalloo AK, Luo FR, Guo A, Paranjpe PV, Lee SH, Vyas V, Rubin E, and Sinko PJ (2004) Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Med 2:16.
21. Litman T, Skovsgaard T, and Stein WD (2003) Pumping of drugs by P-glycoprotein: a two-step process? J Pharmacol Exp Ther 307:846-853.
22. Litman T, Zeuthen T, Skovsgaard T, and Stein WD (1997) Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 61:169-176.
23. Loo TW and Clarke DM (2005) Recent progress in understanding the mechanism of Pglycoprotein-mediated drug efflux. J Membr Biol 206:173-185.
24. Lugo MR and Sharom FJ (2005) Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry 44:643-655.
25. Nies AT, Schwab M, and Keppler D (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545-568.
26. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
27. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, and Polli JW (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
28. Shapiro AB and Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137.
29. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
30. Solazzo M, Fantappiè O, D'Amico M, Sassoli C, Tani A, Cipriani G, Bogani C, Formigli L, and Mazzanti R (2009) Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res 69:7235-7242.
31. Sun H and Pang KS (2008) Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos 36:102-123.
32. Tang F, Horie K, and Borchardt RT (2002) Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:773-779.
33. Taub ME, Podila L, Ely D, and Almeida I (2005) Functional assessment of multiple Pglycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 33:1679-1687.
34. Taylor JR (1997). An Introduction to Error Analysis: The Study of Uncertainties in Physical Measurements, 2nd ed, Chapter 3, pp. 45-79, University Science Books, Herndon, VA.
35. Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton A, Ellens H, and Bentz J (2005) The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys J 88:715-738.
36. Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, and Bentz J (2004) Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 93:2108-2123.
37. Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, and Hidalgo IJ (2008) Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm 356:12-18.
38. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, and Efferth T (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238-245.
39. Zong J and Pollack GM (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther 306:556-562.